{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:43:36Z","timestamp":1787510616930,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015696","name":"National Health Insurance Service Ilsan Hospital","doi-asserted-by":"crossref","award":["NHIMC2018CR043"],"award-info":[{"award-number":["NHIMC2018CR043"]}],"id":[{"id":"10.13039\/501100015696","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The gene encoding fibroblast growth factor receptor 1 (\n                      <jats:italic>FGFR1<\/jats:italic>\n                      ) is emerging as a therapeutic and prognostic biomarker in various cancer types, including head and neck squamous cell carcinoma (SCC). Here, we investigated the clinicopathologic implication of\n                      <jats:italic>FGFR1<\/jats:italic>\n                      gene amplification and protein overexpression in hypopharyngeal and laryngeal SCC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fluorescence in situ hybridization and immunohistochemistry were performed to determine FGFR1 gene amplification and protein overexpression in 209 surgically resected cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification observed in 8 (8\/66, 12.1%; 6 hypopharynx and 2 larynx) patients and high FGFR1 expression in 21 (21\/199, 10.6%) patients significantly correlated with lymph node metastasis and advanced pathological stages.\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification was also associated with worse disease-free survival in multivariate analysis (hazard ratio\u2009=\u20094.527,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.032). High FGFR1 expression was more frequently observed, consistent with the worsening of the degree of histologic differentiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification may serve as an independent prognostic factor for disease-free survival in hypopharyngeal and laryngeal SCC. Aberrant FGFR signaling caused by\n                      <jats:italic>FGFR1<\/jats:italic>\n                      gene amplification or protein overexpression may play a crucial role in the malignant evolution and progression of hypopharyngeal and laryngeal SCC, and offer novel therapeutic opportunities in patients with hypopharyngeal and laryngeal SCC that usually lack specific therapeutic targets.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06792-7","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T10:02:59Z","timestamp":1587636179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Eun Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Ah","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Woo","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyang Ae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Och","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"issue":"10","key":"6792_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jnci\/djk179","volume":"99","author":"M Hashibe","year":"2007","unstructured":"Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the international head and neck Cancer epidemiology consortium. J Natl Cancer Inst. 2007;99(10):777\u201389.","journal-title":"J Natl Cancer Inst"},{"key":"6792_CR2","volume-title":"WHO classification of head and neck Tumours","author":"AK El-Naggar","year":"2017","unstructured":"El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. WHO classification of head and neck Tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2017.","edition":"4"},{"issue":"6","key":"6792_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jnci\/djn025","volume":"100","author":"ML Gillison","year":"2008","unstructured":"Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407\u201320.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6792_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"6792_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdr006","volume":"22","author":"MR Posner","year":"2011","unstructured":"Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22(5):1071\u20137.","journal-title":"Ann Oncol"},{"issue":"6","key":"6792_CR6","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1365-2559.2011.04169.x","volume":"60","author":"JS Lewis Jr","year":"2012","unstructured":"Lewis JS Jr, Ukpo OC, Ma XJ, Flanagan JJ, Luo Y, Thorstad WL, Chernock RD. Transcriptionally-active high-risk human papillomavirus is rare in oral cavity and laryngeal\/hypopharyngeal squamous cell carcinomas--a tissue microarray study utilizing E6\/E7 mRNA in situ hybridization. Histopathology. 2012;60(6):982\u201391.","journal-title":"Histopathology."},{"issue":"6","key":"6792_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"32","key":"6792_CR8","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294\u2013301.","journal-title":"J Clin Oncol"},{"issue":"7536","key":"6792_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576\u201382..","journal-title":"Nature"},{"key":"6792_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.03.015","volume":"46","author":"N Hallinan","year":"2016","unstructured":"Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K. Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev. 2016;46:51\u201362.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"6792_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855\u201362.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6792_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","volume":"43","author":"K Freier","year":"2007","unstructured":"Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, Radlwimmer B, Lichter P, Joos S. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2007;43(1):60\u20136.","journal-title":"Oral Oncol"},{"issue":"15","key":"6792_CR13","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-15-1874","volume":"22","author":"K Koole","year":"2016","unstructured":"Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM. FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 2016;22(15):3884\u201393.","journal-title":"Clin Cancer Res"},{"key":"6792_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.12.016","volume":"91","author":"C Dubot","year":"2018","unstructured":"Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer. 2018;91:47\u201355.","journal-title":"Eur J Cancer"},{"issue":"1","key":"6792_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00432-017-2528-x","volume":"144","author":"TS Clauditz","year":"2018","unstructured":"Clauditz TS, B\u00f6ttcher A, Hanken H, Borgmann K, Sauter G, Wilczak W, Grob T, M\u00fcnscher A. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck. J Cancer Res Clin Oncol. 2018;144(1):53\u201361.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"6792_CR16","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/modpathol.2013.58","volume":"26","author":"F Goke","year":"2013","unstructured":"Goke F, Bode M, Franzen A, Kirsten R, Goltz D, Goke A, Sharma R, Boehm D, Vogel W, Wagner P, et al. Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol. 2013;26(10):1298\u2013306.","journal-title":"Mod Pathol"},{"issue":"4","key":"6792_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40291-016-0204-5","volume":"20","author":"K Koole","year":"2016","unstructured":"Koole K, Clausen MJ, van Es RJ, van Kempen PM, Melchers LJ, Koole R, Langendijk JA, van Diest PJ, Roodenburg JL, Schuuring E, et al. FGFR family members protein expression as prognostic markers in Oral cavity and Oropharyngeal squamous cell carcinoma. Mol Diagn Ther. 2016;20(4):363\u201374.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"6792_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-015-0374-9","volume":"11","author":"NA Ipenburg","year":"2016","unstructured":"Ipenburg NA, Koole K, Liem KS, van Kempen PM, Koole R, van Diest PJ, van Es RJ, Willems SM. Fibroblast growth factor receptor family members as prognostic biomarkers in head and neck squamous cell carcinoma: a systematic review. Target Oncol. 2016;11(1):17\u201327.","journal-title":"Target Oncol"},{"issue":"19","key":"6792_CR19","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1002\/cncr.30135","volume":"122","author":"SH Lim","year":"2016","unstructured":"Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: a single-arm, phase 2 study. Cancer. 2016;122(19):3024\u201331.","journal-title":"Cancer."},{"issue":"6","key":"6792_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11523-017-0513-6","volume":"12","author":"N Hashemi-Sadraei","year":"2017","unstructured":"Hashemi-Sadraei N, Hanna N. Targeting FGFR in squamous cell carcinoma of the lung. Target Oncol. 2017;12(6):741\u201355.","journal-title":"Target Oncol"},{"issue":"1","key":"6792_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-015-3301-y","volume":"150","author":"F Andre","year":"2015","unstructured":"Andre F, Cortes J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat. 2015;150(1):1\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"6792_CR22","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","volume":"21","author":"M Touat","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR signaling in Cancer. Clin Cancer Res. 2015;21(12):2684\u201394.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"6792_CR23","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-14-3357","volume":"21","author":"F Goke","year":"2015","unstructured":"Goke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Goke A, et al. FGFR1 expression levels predict BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clin Cancer Res. 2015;21(19):4356\u201364.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6792_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/era.11.20","volume":"11","author":"P Specenier","year":"2011","unstructured":"Specenier P, Vermorken JB. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2011;11(4):511\u201324.","journal-title":"Expert Rev Anticancer Ther"},{"key":"6792_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC cancer staging manual \/ American Joint Committee on Cancer","author":"MBESB Amin","year":"2017","unstructured":"Amin MBESB. AJCC cancer staging manual \/ American Joint Committee on Cancer. 8th ed. New York: Springer; 2017.","edition":"8"},{"issue":"9","key":"6792_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.ejca.2012.03.007","volume":"48","author":"S Couraud","year":"2012","unstructured":"Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers--a review. Eur J Cancer. 2012;48(9):1299\u2013311.","journal-title":"Eur J Cancer"},{"issue":"3","key":"6792_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119245","volume":"10","author":"K Kim","year":"2015","unstructured":"Kim K, Kim JS. The association between alcohol consumption patterns and health-related quality of life in a nationally representative sample of south Korean adults. PLoS One. 2015;10(3):e0119245.","journal-title":"PLoS One"},{"issue":"7","key":"6792_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/JTO.0000000000000562","volume":"10","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, et al. Fibroblast growth factor receptor 1 and related ligands in small-cell lung Cancer. J Thorac Oncol. 2015;10(7):1083\u201390.","journal-title":"J Thorac Oncol"},{"issue":"31","key":"6792_CR29","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.18.00684","volume":"36","author":"C Fakhry","year":"2018","unstructured":"Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, Bell D, Lingen MW, Harichand-Herdt S, Thibo J, et al. Human papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the College of American Pathologists Guideline. J Clin Oncol. 2018;36(31):3152\u201361.","journal-title":"J Clin Oncol"},{"issue":"5","key":"6792_CR30","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ijc.20740","volume":"114","author":"AL Carvalho","year":"2005","unstructured":"Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114(5):806\u201316.","journal-title":"Int J Cancer"},{"issue":"15","key":"6792_CR31","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.ejca.2015.07.043","volume":"51","author":"G Gatta","year":"2015","unstructured":"Gatta G, Botta L, Sanchez MJ, Anderson LA, Pierannunzio D, Licitra L. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study. Eur J Cancer. 2015;51(15):2130\u201343.","journal-title":"Eur J Cancer"},{"issue":"62","key":"6792_CR32","doi-asserted-by":"publisher","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","volume":"2","author":"J Weiss","year":"2010","unstructured":"Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93.","journal-title":"Sci Transl Med"},{"issue":"6","key":"6792_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/JCO.2012.43.8622","volume":"31","author":"HR Kim","year":"2013","unstructured":"Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 2013;31(6):731\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"6792_CR34","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.18632\/oncotarget.2944","volume":"6","author":"HS Kim","year":"2015","unstructured":"Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung DH, Shin SK, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget. 2015;6(4):2562\u201372.","journal-title":"Oncotarget."},{"issue":"5","key":"6792_CR35","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085\u201394.","journal-title":"Cancer Res"},{"issue":"1","key":"6792_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186185","volume":"13","author":"J Monico","year":"2018","unstructured":"Monico J, Miller B, Rezeanu L, May W, Sullivan DC. Fibroblast growth factor receptor 1 amplification in laryngeal squamous cell carcinoma. PLoS One. 2018;13(1):e0186185.","journal-title":"PLoS One"},{"issue":"2","key":"6792_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/his.13739","volume":"74","author":"B Mariz","year":"2019","unstructured":"Mariz B, Soares CD, de Carvalho MGF, Jorge-Junior J. FGF-2 and FGFR-1 might be independent prognostic factors in oral tongue squamous cell carcinoma. Histopathology. 2019;74(2):311\u201320.","journal-title":"Histopathology."},{"issue":"8","key":"6792_CR38","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/bjc.2013.550","volume":"109","author":"PT Nguyen","year":"2013","unstructured":"Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N, Takata T. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer. 2013;109(8):2248\u201358.","journal-title":"Br J Cancer"},{"issue":"11","key":"6792_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217451","volume":"14","author":"AH Osada","year":"2019","unstructured":"Osada AH, Endo K, Kimura Y, Sakamoto K, Nakamura R, Sakamoto K, Ueki K, Yoshizawa K, Miyazawa K, Saitoh M. Addiction of mesenchymal phenotypes on the FGF\/FGFR axis in oral squamous cell carcinoma cells. PLoS One. 2019;14(11):e0217451.","journal-title":"PLoS One"},{"issue":"50","key":"6792_CR40","doi-asserted-by":"publisher","first-page":"83424","DOI":"10.18632\/oncotarget.13117","volume":"7","author":"WS Brown","year":"2016","unstructured":"Brown WS, Akhand SS, Wendt MK. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition. Oncotarget. 2016;7(50):83424\u201336.","journal-title":"Oncotarget."},{"issue":"6","key":"6792_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038972","volume":"7","author":"DC Tomlinson","year":"2012","unstructured":"Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA. FGFR1-induced epithelial to mesenchymal transition through MAPK\/PLCgamma\/COX-2-mediated mechanisms. PLoS One. 2012;7(6):e38972.","journal-title":"PLoS One"},{"issue":"27","key":"6792_CR42","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1038\/onc.2015.426","volume":"35","author":"H Kotani","year":"2016","unstructured":"Kotani H, Ebi H, Kitai H, Nanjo S, Kita K, Huynh TG, Ooi A, Faber AC, Mino-Kenudson M, Yano S. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene. 2016;35(27):3587\u201397.","journal-title":"Oncogene."},{"issue":"11","key":"6792_CR43","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/carcin\/bgx091","volume":"38","author":"Y Adachi","year":"2017","unstructured":"Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, Inase N, Yano S, Ebi H. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. Carcinogenesis. 2017;38(11):1063\u201372.","journal-title":"Carcinogenesis."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06792-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T19:07:10Z","timestamp":1618686430000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06792-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6792"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06792-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"30 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Institutional Review Board of Severance Hospital (4\u20132015-0954) and National Health Insurance Service Ilsan Hospital (NHIMC 2018\u201304-021). Informed consent was waived owing to the retrospective nature of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}